
Actelion says blood pressure drug Uptravi now available in Germany
pharmafile | June 15, 2016 | News story | Research and Development, Sales and Marketing |Â Â Actelion, EU, blood pressure, product launchÂ
Actelion (SIX: ATLN) said its high blood pressure drug Uptravi (selexipag) is now available in Germany.
The European Commission granted marketing authorization for the drug to treat pulmonary arterial hypertension in May.
Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH). The company said the drug showed efficacy in long-term trials.
The EU label for Uptravi was based in part on the Phase III study, whose main findings were published in the New England Journal of Medicine in December last year.
Michael Danzl, General Manager of Actelion Germany, said: “The availability of Uptravi is a milestone for PAH patients in Germany, where until now, the options for treatments targeting the prostacyclin pathway have been limited, and were burdensome for the patients. With Uptravi, there is now an oral option in all three established treatment pathways.”
The safety of Uptravi has been evaluated in a long-term, study with 1,156 patients with symptomatic PAH. The exposure to Uptravi in this trial was up to 4.2 years with median duration of exposure of 1.4 years.
Adverse reactions occurring more frequently on Uptravi were headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, flushing, arthralgia, anemia, decreased appetite and rash.
Anjali Shukla
Related Content

Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …

Sarclisa recommended for EU approval in newly diagnosed multiple myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi’s …

EU approval granted for rare kidney disease treatment
The EU has granted marketing authorisation (MA) for Filspari – CSL Vifor and Travere Therapeutics’ …






